Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claudia Gottstein

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Molecular Therapy. Methods & Clinical Development|August 28, 2019
Site-Specific Glycation and Chemo-enzymatic Antibody Sortagging for the Retargeting of rAAV6 to Inflamed EndotheliumHannah A Pearce, Hongwei Qian, Timothy U Connell, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|February 9, 2016
Molecular engineering of high affinity single-chain antibody fragment for endothelial targeting of proteins and nanocarriers in rodents and humansColin F Greineder, Elizabeth D Hood, Anning Yao, et al.
Blood|November 30, 2007
Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculatureBi-Sen Ding, Nankang Hong, Juan-Carlos Murciano, et al.
Blood|July 26, 2003
The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphomaPeter Borchmann, John F Treml, Hinrich Hansen, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|April 6, 2022
A Standardized Investigational Ki-67 Immunohistochemistry Assay Used to Assess High-Risk Early Breast Cancer Patients in the monarchE Phase 3 Clinical Study Identifies a Population With Greater Risk of Disease Recurrence When Treated With Endocrine Therapy AloneMonika D Polewski, Gitte B Nielsen, Ying Gu, et al.
Nature Medicine|January 3, 2025
Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trialJessica S W Borgers, Divya Lenkala, Victoria Kohler, et al.
Nature Medicine|August 5, 2025
Publisher Correction: Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trialJessica S W Borgers, Divya Lenkala, Victoria Kohler, et al.
Nature Communications|February 5, 2026
NEO-STIM advances personalized neoantigen-specific adoptive T cell therapyDivya Lenkala, Jessica Kohler, Brian McCarthy, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Molecular Therapy. Methods & Clinical Development|August 28, 2019
Site-Specific Glycation and Chemo-enzymatic Antibody Sortagging for the Retargeting of rAAV6 to Inflamed EndotheliumHannah A Pearce, Hongwei Qian, Timothy U Connell, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|February 9, 2016
Molecular engineering of high affinity single-chain antibody fragment for endothelial targeting of proteins and nanocarriers in rodents and humansColin F Greineder, Elizabeth D Hood, Anning Yao, et al.
Blood|November 30, 2007
Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculatureBi-Sen Ding, Nankang Hong, Juan-Carlos Murciano, et al.
Blood|July 26, 2003
The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphomaPeter Borchmann, John F Treml, Hinrich Hansen, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|April 6, 2022
A Standardized Investigational Ki-67 Immunohistochemistry Assay Used to Assess High-Risk Early Breast Cancer Patients in the monarchE Phase 3 Clinical Study Identifies a Population With Greater Risk of Disease Recurrence When Treated With Endocrine Therapy AloneMonika D Polewski, Gitte B Nielsen, Ying Gu, et al.
Nature Medicine|January 3, 2025
Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trialJessica S W Borgers, Divya Lenkala, Victoria Kohler, et al.
Nature Medicine|August 5, 2025
Publisher Correction: Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trialJessica S W Borgers, Divya Lenkala, Victoria Kohler, et al.
Nature Communications|February 5, 2026
NEO-STIM advances personalized neoantigen-specific adoptive T cell therapyDivya Lenkala, Jessica Kohler, Brian McCarthy, et al.
Pageof 2